Abstract
Researchers have isolated a novel bacterial strain, Marinomonas sp. ef1, from a prokaryotic consortium associated with the Antarctic psychrophilic ciliate Euplotes focardii. Phylogenetic analysis reveals a close relationship to other Antarctic marine bacteria, specifically M. polaris. Whole-genome sequencing identified five genomic islands likely acquired through horizontal gene transfer (HGT), including genes for the nitroreductase superfamily. These enzymes enable the bacterium to perform "green synthesis" of silver nanoparticles (AgNPs) at a mild 22°C. The resulting nanoparticles (30–50 nm) are naturally stabilized by bacterial proteins and exhibit potent antimicrobial activity against common human pathogens while remaining non-toxic to human skin cells.
Introduction
The global threat of multi-drug resistant "superbugs" has accelerated the search for alternative antimicrobial agents. Silver nanoparticles (AgNPs) are highly effective against a broad spectrum of bacteria and fungi. However, traditional industrial production relies on energy-intensive physico-chemical methods involving toxic reducing agents. This study investigates the extreme environment of the Antarctic to find specialized microbes capable of sustainable, biological nanoparticle production.
Methods and Genomic Analysis
The new strain, Marinomonas sp. ef1, was isolated from the ciliate Euplotes focardii and characterized using 16S rDNA sequencing and Whole Genome Sequencing (WGS). Bioinformatics tools were employed to identify Genomic Islands (GEIs)—clusters of genes acquired from other species via HGT.
For biosynthesis, bacterial biomass was incubated with 1 mM silver nitrate (AgNO3) at 22°C. The resulting AgNPs were purified and characterized using Transmission Electron Microscopy (TEM), X-ray Diffraction (XRD), and Fourier Transform Infrared (FTIR) spectroscopy. Biological efficacy was measured against 12 clinical pathogens, and biocompatibility was assessed using human dermal fibroblast (NHDF) assays.
Horizontal Gene Transfer and Metabolic Adaptation
A key finding of the study is that the ability to produce AgNPs is likely an acquired trait. Marinomonas sp. ef1 possesses specific enzymes, such as the nitroreductase YfkO, located within genomic islands. These "borrowed" genes allow the bacterium to detoxify silver ions by converting them into solid nanoparticles. This mechanism may provide a dual ecological benefit: detoxifying the immediate environment and protecting the host ciliate from pathogenic infections.
While HGT is evident, the authors noted that definitively identifying the donor organisms remains challenging due to faint evolutionary signals in some gene clusters.
Nanoparticle Characterization and Efficacy
The biosynthesized AgNPs were spherical, relatively small, and highly stable. FTIR analysis confirmed that the particles are naturally "capped" by bacterial proteins, which prevents aggregation and likely enhances their biological stability.
Key results include:
- Size and Stability: Average particle size of 30–50 nm with a negative zeta potential of -27.1 mV.
- Antimicrobial Potency: The AgNPs outperformed conventional antibiotics like Ampicillin against several pathogens, including S. aureus and E. coli. The Minimum Inhibitory Concentration (MIC) was as low as 3.12 µg/ml for Proteus mirabilis.
- Biocompatibility: At therapeutic concentrations (below 10 µg/ml), the nanoparticles showed no significant cytotoxic effect on human dermal fibroblasts, suggesting potential for topical medical applications.
Conclusion
This research provides the first report of AgNP biosynthesis by a Marinomonas strain. By leveraging genes acquired through horizontal gene transfer, Marinomonas sp. ef1 serves as an efficient microbial factory for producing stable, bioactive nanoparticles. These findings highlight the potential of Antarctic microbiota as a source for sustainable biotechnological solutions in the fight against antibiotic resistance.
Summary updated